Osteosarcoma is highly metastatic tumor that mainly occurs in juvenile patients. Although the prognosis of these patients have improved substantially through the development of effective adjuvant and neoadjuvant regimens of chemotherapy, ＞20% of patients still die as a result of tumor metastasis and unresectable tumor.
has been extensively studied, and PPARγ agonists have been shown to have direct effects on tumor cells, including breast, colon, lung, stomach, and liver cancer.
2)
Thiazolidinedione (TZD) groups are synthetic ligands of PPARγ , including troglitazone, rosiglitazone, pioglitazone, and ciglitazone, which have been used widely in patient with insulin-resistant diabetes mellitus.
3) It has been reported that TZD inhibits the cell proliferation and colony formation via inducing apoptosis in several human cancer cells. Thus, we hypothesized that the upregulation of PTEN by transfection could enhance tumor cell growth inhibition by troglitazone.
In present study, we investigated the effects of PTEN expression level on the cell growth, and the response of troglitazone in osteosarcoma cells.
Materials and Methods

Cell culture
The human osteosarcoma cell lines (U-2OS) were purchased from 10% (v/v) fetal bovine serum and 2 mM glutamine, 100 units/ml of penicillin, 10 μ g/ml of streptomycin, and 2.5 μ g/ml of amphotericin B.
PPARγ agonists, troglitazone was as obtained from Sigma-Aldrich, Inc (St. Louis, MO).
Cell proliferation assay
The viability of cultured cells was determined by reducing WST-8
(water-soluble tetrazolium salt, (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt) to highly water-soluble formazan as described previously.
7)
After treatment, the cells in 96-well plates were washed twice with PBS and Cell counting kit-8 (CCK-8, Dojindo Lab, Kumamoto, Japan) solution (10 μ l) was added to each well. Cells were then incubated at 37 o C for 1hr. Absorbance was measured at 450 nm with model Spectra MAX Plus (Molecular Devices, Sunnyvale, CA). 
Apoptosis assay
Construction of recombinant plasmids
GFP expression plasmids based on pCDNA with full-length wildtype PTEN and the point mutant C124A (Cys
124
-Ala) PTEN were purchased from Invitrogen (Carlsbad, CA). The plasmids were restrictively digested with HindIII and XbaI, then the full length wildtype and mutant type PTEN mRNA were reclaimed and purified, and then cloned into pCDNA-C1 form pCDNA-C1-WT-PTEN and pCDNA-C124A-PTEN, pCDNA-C1 was treated as a control.
Plasmid transfections
For transfection, U-2 OS cells were seeded in six well plates at 
Statistical analysis
Results
Troglitazone induced cell death of human osteo sarcoma cells
The WST assay was performed to determine the growth inhibition effects of troglitazone on the human osteosarcoma cells at various (Fig. 1A) . The specific concentrations were selected for more detailed studies of troglitazone time-dependence (Fig. 1B) .
Troglitazone treatment decreased U-2OS cell numbers significantly within 24 hours and this inhibition was maintained for 72 hours. As shown in Fig. 1 , troglitazone inhibited U-2OS cell proliferation in a concentration and time-dependent manner.
Troglitazone caused apoptotic death of U2OS cells
We investigated the possible involvement of apoptosis induction by troglitazone that might have contributed to the cell necrosis. After 48 hr treatment, there were primarily three populations of cells: cells that were viable and not undergoing apoptosis (Annexin V-FICT and PI negative) and cells undergoing apoptosis (Annexin V-FITC positive and PI negative). Another population of cells was observed to be Annexin V-FITC and PI positive, indicating that they were in end stage apoptosis or already dead (Fig. 2) . By flow cytometric analysis, troglitazone increased the apoptosis and necrosis of cells that peak to 27.2%, 48.12%, 68.17% and 80.27%, respectively.
Troglitazone stimulated PTEN expression of U2OS cells in a dose dependent manner
To evaluate the effect of troglitazone on PTEN expression in osteosarcoma cells, the U-2OS cells were treated for 6 hours with various concentration of troglitazone. Results of Western blot analysis showed that troglitazone treatment (0, 5, 10, 20, and 30 μ M for 6 hr) of U-2OS cells markedly induced protein levels of PTEN in a dosedependent manner (Fig. 3) . This result suggested that troglitazone enhanced PTEN expression in a dose-dependent manner.
Establishment of PTEN overexpression osteo sarcoma cells using transfection
To elucidate the mechanism of troglitazone induced apoptosis, we established PTEN-over expression U2-OS cells line through transfection with wild and mutant plasmid DNA. Morphologically, the two pools (wild and mutant cells) were similar to the native cells. We first confirmed activities of wild and mutant PTEN expressing cells by Western blotting (Fig. 4) . However, the PTEN expression in the U-2OS cells declined gradually after being treated with troglitazone for a longer time period (e.g. 72 hrs), since the activity of plasmid transfection was decreased with time. In summary, our results demonstrated that troglitazone, a syn- 
